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Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring
disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical
value as an alternative tumour source for the detection clinically targetable mutations for the assessment
of response to therapy. This review provides a critical summary of the evidence that gives credence to the
utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps
required for its implementation into clinical settings.
© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Melanoma is the most aggressive form of skin cancer, representing only 10% of all skin cancers but responsible for more than
80% of skin cancer-related deaths. The advent of novel therapeutic
approaches over the past several years has transformed the clinical
management of metastatic melanoma [1]. The combination of BRAF
and MEK inhibitors, commonly used to treat melanoma patients
with BRAF mutations, can rapidly reduce disease burden and
improve patient status [2e4]. Nevertheless, acquired resistance to
these treatments, as a consequence of clonal evolution and selection, commonly develops within 12 months [5e7]. Antibodymediated blockade of immune checkpoints, particularly the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell-death protein 1 (PD-1), have markedly improved
patient outcome in the last 5 years [8e12]. There is evolving evidence that the use of immune checkpoint inhibitors can lead to
durable responses and prolonged survival for a small proportion of
patients. However, a signiﬁcant number of patients are still incapable of achieving a meaningful beneﬁt from immunotherapy. In
addition, immune checkpoint inhibitors are costly and have the
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potential to cause substantial toxicity [13e16]. Major efforts have
been made to better identify factors that can guide patient selection
for speciﬁc treatments, monitor disease evolution, and aid in clinical decision making in melanoma.
In recent years, much attention has been focused on utilising
circulating cell-free DNA (cfDNA), speciﬁcally the tumour-derived
cfDNA (ctDNA), as a biomarker of disease status in metastatic
cancer patients [17e19]. cfDNA are short nucleic fragments (~166
bp) found in plasma, which are thought to be released as a result of
cell apoptosis and/or necrosis [18,20]. In cancer patients, the high
cell turnover rate of tumours results in the release of ctDNA.
Numerous studies have shown that ctDNA carries genetic information from the entire tumour genome and can therefore provide
insight into clonal heterogeneity and evolution of all solid cancers
present at any one time [18,21]. Thus, the presence of ctDNA in the
blood provides information via a minimally invasive ‘liquid biopsy’,
eliminating the morbidity associated with serial sampling of tumours for monitoring patients with advanced solid cancers.
Various studies in breast, lung and colorectal cancers have
demonstrated the potential application of ctDNA analysis at each
stage of clinical management: early diagnosis [18,22], molecular
proﬁling [21,23e25], prognostication [18,26,27], detection of residual disease [28,29], monitoring response and clonal evolution
[30e34]. Lastly, the recent approvals by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) for
detection of the tyrosine kinase resistant clone EGFR p.T790M
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mutation in plasma as a companion diagnostic for second-line
treatment of metastatic EGFR-mutant non-small cell lung cancer
(NSCLC) [35e37], and the inclusion of ctDNA analysis into multiple
clinical trials (ClinicalTrials.gov), signals the recent integration of
this form of biomarker into routine clinical oncology.
While several studies have shown the efﬁcacy of utilising ctDNA
for monitoring of BRAF mutant melanomas [38e45], it remains
unutilised in clinical management of melanoma. Here, we review
the existing evidence of the clinical validity of ctDNA as a biomarker
for metastatic melanoma and critically appraise the challenges
ahead for the implementation of this liquid biopsy into melanoma
clinical management.
ctDNA as a predictor of response to therapy and prognosis in
metastatic melanoma
The majority of studies on ctDNA as a biomarker of disease
status in advanced melanoma have been applied to patients treated
with BRAF inhibitors [38,39,42,44,46], via monitoring of the singular BRAFV600 mutation. Notably, these studies have shown that
plasma ctDNA levels prior to commencement of BRAF inhibitor
therapy correlated with response to therapy [38,39,42,44,46].
Moreover, baseline ctDNA levels were consistently found to be
signiﬁcantly associated with overall response rate (ORR) and progression free survival (PFS) (Table 1) [38e41,43]. In particular, the
BREAK-2 study (a phase II trial), aimed at evaluating the safety and
clinical activity of the BRAF-inhibitor dabrafenib, showed that high
basal ctDNA levels correlated with lower overall response rate and
lower PFS to targeted therapy [39]. These results were further
conﬁrmed in a large study (N ¼ 836) that include the BREAK-3,
BREAK-MB and METRIC clinical trials [41]. Overall, these studies
provide sufﬁcient evidence of the predictive value of ctDNA for
response to targeted therapy in melanoma patients.
A small number of studies have evaluated the predictive value
and dynamics of ctDNA in patients treated with immunotherapies.
A study conducted by Lipson et al. [47] showed that the levels of
ctDNA correlated with radiological outcomes in two melanoma
cases treated with immunotherapy. Gray et al. [38] showed that
baseline ctDNA levels predict response to immunotherapy in melanoma patients, and that low basal ctDNA levels were signiﬁcantly
associated with long term clinical beneﬁt. More recently, Lee et al.
[48] reported on a longitudinal assessment of ctDNA in metastatic
melanoma patients treated with PD1 inhibitors. In this study,
ctDNA levels at baseline and early during treatment provided an
accurate prediction of tumour response, PFS and OS. Nevertheless, a
prospective study of survival in a larger cohort of patients is urgently required to validate the predictive value of ctDNA in melanoma patients treated with immunotherapy.
ctDNA as an indicator of tumour burden to monitor response
to treatment
Previous studies in melanoma have demonstrated a signiﬁcant
association between ctDNA levels and tumour burden. Levels of
ctDNA were found to signiﬁcantly correlate with clinical serological
markers of disease burden, namely lactate dehydrogenase (LDH),
S100 calcium-binding protein B (S100B) and melanoma inhibitory
activity (MIA) [40]. However, ctDNA proved to be a more accurate
measure due to its tumour speciﬁc origin and ability to expand over
a dynamic range of 4e5 log scale units [40,42,49]. Conversely, LDH,
which is used to stage metastatic melanoma, has a narrow dynamic
range of less than 2 log units and is affected by non-speciﬁc inﬂammatory conditions. Thus, ctDNA appears to be a better bloodbased biomarker for deﬁning patient tumour status in the clinic.
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The ability of ctDNA to accurately reﬂect tumour burden makes
it viable for tracking treatment response in metastatic melanoma
patients. Studies have consistently shown that ctDNA levels
correlate with imaging scans showing a decrease in tumour burden,
in response to targeted therapy [38,42]. For example, Tsao et al. [50]
demonstrated that changes in ctDNA levels accurately reﬂected the
contemporaneous disease status of six immunotherapy cases during disease course. Conversely, an increase in ctDNA levels during
treatment is an accurate indication of disease progression [38,42].
Gray et al. [38] provided evidence that increasing ctDNA levels can
precede radiological evidence of disease progression and acquired
resistance to targeted therapy. Finally, a recent study by Wong et al.
[45] highlighted ctDNA quantiﬁcation as a suitable complementary
modality to functional imaging for real-time monitoring of tumour
burden. Overall, the signiﬁcant correlation between plasma DNA
and disease status suggests that ctDNA can be utilised in the clinic
as a complement to imaging scans to aid in the assessment of
melanoma tumour dynamics.
In the era of immunotherapy and durable responses, ctDNA
surveillance in patients could also provide clinicians with important adjunct information. In particular, for patients who have achieved complete response but are otherwise still undergoing
treatment, ctDNA levels can be used to determine if cessation of
treatment is warranted. Conversely, for patients that have ceased
treatment, continuous monitoring of ctDNA levels, concurrently or
in parallel to imaging scans, can help identify emergence of recurrence. Thus, ctDNA could have clinical value in the surveillance of
patients that are successfully treated.
Monitoring of clonal evolution and emergence of resistance
to targeted therapy
Tumour heterogeneity poses a signiﬁcant challenge in patients
treated with targeted therapy. While the selective pressure of these
targeted therapies on dominant clones can result in tumour
regression, these therapies can also drive an increase in the population of resistant clones. As ctDNA is derived from apoptosis of
any tumour cell, it is valuable for the identiﬁcation of sub-clonal
mutant cell populations in a tumour and/or mechanisms underlying resistance to targeted therapies.
Recent studies have demonstrated the utility of ctDNA for the
identiﬁcation of mutations responsible for driving acquired resistance to BRAF and/or MEK inhibitors in melanoma [38,42]. The
NRAS mutation, particularly at codon 61 (p.Q61K/R), became
evident in the ctDNA of patients that developed acquired resistance
to BRAF inhibitor treatments, even apparent prior to detection of
radiological progression in some cases [38,42]. Mutations in the
NRAS gene reactivate the mitogen-activated protein kinase (MAPK)
pathway, which ensures the survival of melanoma tumours despite
substantial BRAF inhibition [5,51]. In addition, recent reports have
identiﬁed other potential mechanisms of resistance to targeted
therapies either during treatment or at disease progression [42,45].
Overall, these results advocate for the implementation of serial
ctDNA sampling to identify mutational mechanisms of drug resistance to allow for intervention or change of therapies prior to rapid
escalation of tumour burden, which can be irreversible and fatal.
Furthermore, ctDNA can also be used delineate those patients with
intrinsic resistance, so BRAF inhibitors should be used in caution
with these cases. Nevertheless, resistance to BRAF inhibition is not
always driven by DNA mutations, and thus methodologies for an
accurate and comprehensive assessment of tumour transcriptome
are also needed.
It is important to note that for melanoma patients that harbour a
BRAF mutation, targeted therapy remains the ﬁrst-line treatment,
particularly in Australia [52]. Given the high propensity of patients to
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Table 1
Studies that shows utility of ctDNA as a biomarker of disease status in metastatic melanoma.
Publication date

No. of patients

Stage

Mutations

Method

Analytical
sensitivity

Treatment

Diagnostic sensitivity

Associated with or
prognostic

Ascierto et al.

2014

91

IV

BRAFV600E/K

BEAMing

Not reported

Combination
Dab þ Tra

79e89%

Tumour burden,
ORR & PFS

Bettegowda et al.

2014

20

IV

BRAF

BEAMing
PCR-Ligation
or Safe-SeqS

Not reported

e

85%

Not assessed

Lipson et al.

2014

12

IV

BRAF
cKIT
NRAS
TERT

BEAMing & targeted
reseq (TERT)

0.01%

Ipi/BMS-936559

50% (BRAF unbiased)

Not assessed

Sanmamed et al.

2015

20

BRAFV600E

BioRad
ddPCR

0.005%

Vem and Dab

84%

Tumour burden,
PFS & OS

Tsao et al.

2015

6

IV

BRAFV600E/K, NRASQ61H

BioRad
ddPCR

Not reported

Dabrafenib and MK3475

Not assessed

Not assessed

Gray et al.

2015

48

IV

BRAFV600E/K, NRASQ61K,R,L

BioRad
ddPCR

Not reported

Vem, Dab, Combi, Pembro,
Nivo and Ipi

73%

ORR & PFS

Gonzales-Cao et al.

2015

22

IV

BRAFV600E

AS-PCR

0.005%

Vem and Dab

50%

PFS & OS

V600E/K

Santiago-Walker et al.

2015

836

IV

BRAF

BEAMing

Not reported

Dabrafenib and/or Trametinib

88%

ORR, PFS & OS

Girotti et al.

2015

214

II, III and IV

BRAFV600E/K, NRASQ61R/K,
PIK3CAE545K

WES, Targeted
re-sequencing

Not reported

Vem, Dab, Combi, Pembro,
Nivo and Ipi

Not assessed

ORR &PFS

Chang et al.

2016

31

IV

BRAFV600E/K, NRASQ61K,R,L

BioRad
ddPCR

Not reported

e

80%

Not assessed

Knol et al.

2016

38

IIIc, IV

BRAFV600

Therascreen BRAF
RGQ Kit (Qiagen)

Not reported

Combi, BRAF inhibitor

Not assessed

OS

Lee et al.

2017

76

IV

BRAF
NRAS
KIT

ddPCR

Not reported

Ipi, Pembro and Nivo

Not assessed

PFS & OS

Wong et al.

2017

52

IV

BRAF
NRAS
TERT

WES
dPCR
Targeted amplicon
(TA) sequencing

0.1%
2%

MAPKi, Immunotherapy

Not assessed

Tumour burden,
PFS
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Fig. 1. ctDNA as an indicator of emerging resistance to targeted therapy. Serial ctDNA level measurement can be used to determine the exact point of emergence of acquired
resistance to targeted therapy. At the point of emerging relapse, the tumour burden, and consequent ctDNA levels are low, therefore immediate change in treatment strategies may
provide optimal clinical beneﬁt in melanoma patients.

develop acquired resistance to BRAF and/or MEK inhibitors, it is
crucial to determine the most appropriate time for switching therapy
for improved overall survival. Tracking of BRAFv600 ctDNA levels and
surveillance of potential mechanisms of acquired resistance, e.g.
NRAS mutations, as patients undergo targeted treatment can help
identify the period when resistance to targeted therapy emerges
(Fig. 1). Modiﬁcation of treatment at the onset of acquired resistance
to targeted therapy, before rampant increase in tumour burden,
potentially increases the response rate to subsequent second-line
immunotherapy treatment. Previous studies have shown that low
tumour burden is correlated with response to immunotherapy [10].
Thus, treatment modiﬁcation prior to full disease escalation could
give patients a better outcome. Nevertheless, ctDNA guided clinical
trials are needed to determine the utility of ctDNA as a catalyst for a
reactive treatment modiﬁcation in melanoma.
ctDNA and the epigenetic landscape in melanoma
Aside from mutations, emerging research have shown that
tumour-speciﬁc gene methylation patterns are detectable in ctDNA
of cancer patients [53e59]. Methylation at the promoter region of
tumour suppressor genes is considered a primary event in carcinogenesis, thus methylated cfDNA could be a promising biomarker
for early detection of cancer.
Previous studies have demonstrated that detection of hypermethylation in the promoter region of genes in ctDNA such as TFPI2,
PTEN, RARB2, RASSF1A and MGMT can signiﬁcantly discriminate
melanoma patients from healthy controls [60e62]. Thus,

methylation studies using cfDNA may be a viable non-invasive
diagnostic biomarker for melanoma. Of note, hypermethylated
ESRI, hypermethylated AIM1 and hypomethylated LINE-1 promoters
in circulating DNA were found to be unfavourable prognostic
markers of melanoma [63,64]. However, the utility of ctDNA for
epigenetic studies in melanoma requires further evaluation,
particularly in relation to the new treatment options, including
early diagnosis, prediction of response, disease monitoring and/or
identifying resistance mechanisms.
Detectable DNA hypermethylation in the RASSF1A promoter in
the serum of melanoma patients has been the most consistently
reported epigenetic modiﬁcation evident in melanoma ctDNA
[60e62,65]. This has been associated not only with reduced overall
survival [62] but is also predictive of worse response to biochemotherapy [63,65]. In addition, a recent report showed that
levels of methylated RASSF1A ctDNA are signiﬁcantly higher in in
situ and metastatic melanoma patients (n ¼ 84) than in healthy
controls (n ¼ 68), with the level of methylated RASSF1A cfDNA
being more elevated in metastatic cases than in early stage melanoma [66]. RASSF1A methylation has also been reported to be
detectable in variety of tumours such as breast [67,68], prostate
[67], lung [68,69] and ovarian cancers [70e73]. Thus, the need for
identiﬁcation of ctDNA methylation markers that are speciﬁc to
melanoma is necessary and useful for diagnostic purposes.
Notably, DNA methylation is not unique to tumour cells. Methylated DNA can be derived from non-tumour cells which can
signiﬁcantly affect the speciﬁcity of methylated ctDNA for diagnostic purposes. Studies clearly linking abnormal methylation
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proﬁles to tumour derived circulating DNA are required to conﬁrm
the tumour speciﬁcity of these methylation proﬁles. Nevertheless,
the preferential presence of methylated DNA in cancer patients
may be an indicator of cancer related processes, and could still
provide relevant diagnostic and prognostic information.
ctDNA analysis e challenges and new frontiers
ctDNA analysis and methodologies
Detection of ctDNA relies on the identiﬁcation of tumour speciﬁc genetic alterations. However, tumour-speciﬁc mutation
proﬁling can be limited by relatively low concentrations of ctDNA.
Advances in technology have been aimed at better detecting lowfrequency mutations. Current methods to detect mutations
include PCR based methods such as BEAMing (beads, emulsion,
ampliﬁcation and magnetics) and droplet digital PCR (ddPCR),
which are known to have limits of detection of 0.01 and 0.001%
respectively [49,74e76].
BEAMing and ddPCR technologies involve ampliﬁcation of DNA
templates within water-oil droplets followed by quantiﬁcation.
While the sensitivity of these technologies allow for detection of
low frequency mutations, pre-identiﬁcation of gene targets is
required. In melanoma, the high frequency of patients that harbours either mutant BRAFV600 (~50%) or NRASQ61 (~20%) enhances
the efﬁcacy of these highly sensitive methodologies for ctDNA
analysis in the majority of cases. However, melanomas that are
wild-type BRAF and/or NRAS, approximately 30% of patients overall,
are more challenging to monitor.
Mutations in the promoter region of the telomerase reverse
transcriptase (TERT) gene, particularly TERTC250T and TERTC228T, are
present in 50e70% of melanomas [77] and are associated with rapid
growing tumours and poor prognosis [78e80]. Detection of TERT
mutations in plasma are therefore an alternative mutant ctDNA for
assessment of melanoma status, as well as a relevant mutation for
prognostication [45]. Nevertheless, the fact that these mutations are
present in the promoter region provides a signiﬁcant challenge.
Stability of cfDNA is highly dependent on its association with the
nucleosome core particle and linker histones, which preferentially
protect it from nuclease cleavage [81]. Given the frequent absence of
nucleosomes in TERT promoter regions, due to its high level of
expression in melanomas [82], it is susceptible to enzymatic cleavage, suggesting that mutations in this region may be less represented
in ctDNA. This hypothesis highlights the need for that further studies
of ctDNA biology prior to its clinical implementation.
It is important to note that while TERT promoter mutations are
common aberrations in melanoma, these tend to co-occur in tumours
with BRAF and/or NRAS mutations [82,83]. Therefore, ctDNA identiﬁcation in TERT, BRAF and NRAS wild-type melanomas would require
interrogation of multiple additional loci using targeted sequencing of
the plasma. Since cfDNA levels range from 1 to 10 ng/ml of plasma in
most patients [18], this presents a signiﬁcant challenge for any library
preparation methodology required for sequencing. In addition, current sequencing technologies have error rates greater than the frequency abundance required for ctDNA analysis [84]. Improvements
in library preparation, particularly addition of unique identiﬁer
barcodes and/or running multiple replicates [85], can increase the
sensitivity of these methods. However, these types of analyses are
currently restricted to highly specialised laboratories.
ctDNA in the cerebro-spinal ﬂuid (CSF) for monitoring of brain
metastasis
A major limitation of ctDNA analysis is its unsuitability as a
biomarker for tracking evolution of tumours that metastasise to the

brain [25,86]. Patients with brain tumours often have low and/or
undetectable ctDNA, suggesting that the blood-brain barrier may
signiﬁcantly impact the release of tumour DNA into the systemic
circulation [25,45,86]. However, studies have shown that ctDNA
kinetics can be derived from cerebro-spinal ﬂuid (CSF), allowing
assessment of tumour dynamics from metastatic tumours in the
brain of patients with melanoma [86,87]. Given the highly invasive
nature of repeated lumbar punctures, the clinical utility of this
approach would need to be clearly vindicated.
ctDNA analysis as a viable marker of residual disease
The potential role of ctDNA in the clinic may extend beyond
merely monitoring disease status of patients with advanced cancers. Plasma DNA analysis may also be exploited for detecting residual disease and/or early relapse in pre-metastatic stages. Recent
prospective studies in breast and colorectal cancers have shown
that detection of ctDNA in plasma after curative resection, either at
post-surgical or serial time points, is signiﬁcantly correlated with
residual disease and eventual recurrence [29,88]. Analysis of ctDNA
may elucidate the presence of residual tumour mass that was not
eradicated by standard treatment, and thus identify patients at high
risk of recurrence.
Detection of residual disease will be particularly useful in high
risk patients after surgical excision of the primary melanoma or
after lymphadenectomy, given the highly aggressive nature of this
cancer. Studies are needed to determine whether ctDNA positivity
in melanoma patients post-surgery is indicative of recurrence.
However, Bettegowda et al. [18] showed that early stage cancers
often present with fewer than 10 copies per 5 ml of plasma. Given
that ctDNA levels correspond signiﬁcantly with tumour burden, the
feasibility of ctDNA detection in stage I-II melanoma patients is
unclear and requires evaluation. However, screening for ctDNA in
stage III and IV melanoma patients after lymph node biopsy, lymphadenectomy or surgical resection of a metastasis could distinguish those patients with residual disease needing further adjuvant
therapies.
ctDNA as a predictor of response to immunotherapy
As indicated above, recent clinical advances with immune
checkpoint inhibitors, anti-CTLA4 anti-PD1ePDL1, have successful
activity in treating melanoma [13,47]. Nevertheless, only a small
cohort of patient respond to immunotherapy, which underscores
the need for biomarkers that can be used to predict response to
immune blockade inhibitors.
Mutations, genetic rearrangements, insertions and deletions
have the capacity to encode novel, cancer speciﬁc neo-antigens.
Activation of T-cells is initiated by the recognition of novel peptides presented as human leukocyte antigens (HLA). Thus, a cancer
mutation can result in the formation of a novel antigenic peptide
recognisable by the surveillance immune system. UV induced
melanomas with a higher mutational burden, irrespective of
whether these are driver mutations, may present a larger number
of novel neoepitopes. As immune checkpoint inhibitors essentially
unleash existing anti-tumour T cell responses, highly mutated tumours are more likely to be sensitive or more responsive to immune checkpoint blockade. Thus, high mutational load may be of
clinical value for patients treated with immunotherapy.
In the last few years, studies have shown that tumour mutational load can be a relevant predictive biomarker for monitoring
responses to immunotherapy, particularly for a PD-1 inhibitor in
NSCLC [89,90], and for CTLA4 inhibition in metastatic melanoma
[81]. Melanomas commonly have the highest mutational load of all
human tumours [91], which might explain their high response
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Fig. 2. Schematic representation of pseudoprogression in patients undergoing immunotherapy. ctDNA levels measurement can be used to distinguish between true progression
(high) and pseudo-progression (low).

rates to anti-PD1 therapy (~30e40%) [92] and anti-CTLA4 monotherapy (15%) [12,13,81,93]. Next-generation sequencing of the
tumour tissue is currently the gold standard for assessment of
tumour mutational load. However, tissue biopsies can be highly
invasive or the tumour may be inaccessible. Recently, a study
showed that ctDNA can comprehensively capture spatial genomic
heterogeneity of metastatic melanoma [45]. Therefore, ctDNA
presents as an easily accessible and suitable surrogate tumour
source for mutational load analysis to predict response to immunotherapy. Given the recent increase in sensitivity of next generation sequencing, it is feasible that ctDNA will be used in the future
to estimate tumour mutational and neoepitope load, as a way
predicting response to immune checkpoint inhibiting therapies.
While immunotherapy provides signiﬁcant clinical beneﬁt in
patients that respond to treatment, delayed tumour regression and
pseudo-progression, which is characterised by inﬁltration of lymphocytes into the tumour giving the appearance of an enlarged
tumour in radiological scans, signiﬁcantly complicate evaluation of
patient response. As ctDNA levels correspond closely with tumour
burden, ctDNA levels provide a measure that allows distinction
between regressing, progressing and pseudo-progressing tumours
(Fig. 2). While it is apparent that ctDNA monitoring provides reliable and highly speciﬁc information regarding disease status of
melanoma patients, further analysis of the kinetics of response in
patients undergoing immunotherapy is needed to conﬁrm its
utility as a companion to radiological assessments.

accessibility and ability to accurately reﬂect disease burden also
makes it a particularly reliable biomarker for the surveillance of
melanoma patients during treatment course. In addition, emerging
studies in epigenetics and residual disease suggest that ctDNA
analysis could be a suitable diagnostic and prognostic maker of
melanoma. As the goal of therapy in metastatic melanoma shifts
from disease stabilisation to longitudinal complete response, ctDNA
can therefore be exploited to provide a real-time assessment of
patient status and, in cases of emerging relapse, be a catalyst for a
reactive approach to treatment modiﬁcation based on the biological changes observed. Nevertheless, clinical trials that looks at
patient outcome as a result of ctDNA-guided clinical decisions are
required before ctDNA can be successfully established as a
melanoma-speciﬁc biomarker in clinical practice.
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